Results 261 to 270 of about 118,448 (336)
Management of xylazine toxicity, overdose, dependence, and withdrawal: A systematic review
The American Journal on Addictions, EarlyView.Abstract Background and Objectives Xylazine, an alpha‐2‐adrenergic agonist, has been increasingly implicated in substance use and overdose crises. However, little is known about its effects on humans. With the growing public health crisis surrounding xylazine, it has become important to recognize and promptly manage symptoms of xylazine toxicity ...
Philipa Owusu‐Antwi +4 more
wiley +1 more source
Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson's disease. [PDF]
Neuroimage Clin, 2020 van der Vegt JPM +7 more
europepmc +1 more source
The American Journal on Addictions, EarlyView.Abstract Background Opioid use disorder (OUD) imposes a significant socioeconomic burden, highlighting the need for new interventions. Objective This study investigated whether exposure to 5‐alpha reductase inhibitors (5αRIs) is associated with a lower risk of developing OUD.
Abdelrahman G. Tawfik +5 more
wiley +1 more source
Andrology, EarlyView.Abstract This is the first episode of a series of four discussions on the differences between males and females, in apparently non‐andrological fields. You will read the transcript of discussions that actually took place at the Endocrinology Unit in Modena, Italy, in the form of the aporetic dialogues of ancient Greece.
Giulia Brigante +7 more
wiley +1 more source
Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders
Andrology, EarlyView.Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret +5 more
wiley +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source